FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for EXJADE (deferasirox) by Novartis Pharmaceuticals Corporation, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Myelodysplastic Syndrome
• Sickle Cell Disease
• Transfusion-dependent Iron Overload

Drugs mentioned

• Exjade (deferasirox)

Snippet

SUPPL AP for EXJADE (DEFERASIROX)